北京市君合（广州）律师事务所 关于 广州万孚生物技术股份有限公司 2025 年第一次临时股东大会的 法律意见书 二零二五年七月 | 北京总部 | 电话: (86-10) 8519-1300 | 上海分所 | 电话: (86-21) 5298-5488 | 广州分所 | 电话: (86-20) 2805-9088 | 深圳分所 | 电话: (86-755) 2939-5288 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 传真: (86-10) 8519-1350 | | 传真: (86-21) 5298-5492 | | 传真: (86-20) 2805-9099 | | 传真: (86-755) 2939-5289 | | 杭州分所 | 电话: (86-571) 2689-8188 | 成都分所 | 电话: (86-28) 6739-8000 | 西安分所 | 电话: (86-29) 8550-9666 | 青岛分所 | 电话: (86-532) 6869-5000 | | | 传真: (86-571) 2689-8199 | | 传真: ( ...

Core Viewpoint - The China Securities Social Development Security Industry Theme Index (CSI Security) has shown mixed performance, with a recent increase of 0.58% and a year-to-date rise of 0.39% [1]. Group 1: Index Performance - The CSI Security Index rose by 2.28% over the past month, but has decreased by 3.03% over the last three months [1]. - The index was established on June 29, 2012, with a base value of 1000.0 points [1]. Group 2: Index Composition - The top ten weighted stocks in the CSI Security Index include: - Huace Testing (9.28%) - Hikvision (7.9%) - Zhongke Shuguang (3.59%) - Wanfu Biology (2.94%) - Greenme (2.88%) - Meiya Optoelectronics (2.77%) - Southern Network Technology (2.48%) - Siwei Liekong (2.48%) - Dahua Technology (2.43%) - Aerospace Zhizhuang (2.4%) [1]. - The index's holdings are primarily listed on the Shenzhen Stock Exchange (67.13%) and the Shanghai Stock Exchange (32.87%) [1]. Group 3: Industry Breakdown - The industry composition of the index includes: - Industrial sector: 42.43% - Information technology: 41.81% - Public utilities: 5.46% - Communication services: 4.97% - Healthcare: 4.88% - Financial sector: 0.45% [2]. Group 4: Index Adjustment Mechanism - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2]. - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2]. Group 5: Related Funds - Public funds tracking the CSI Security Index include Donghai CSI Social Development Security [3].

广州万孚生物技术股份有限公司 | 证券代码：300482 | 证券简称：万孚生物 公告编号：2025-033 | | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | 根据《深圳证券交易所创业板股票上市规则》、《深圳证券交易所可转换公司 债券业务实施细则》的有关规定，广州万孚生物技术股份有限公司（以下简称"公 司"）现将 2025 年第二季度可转换公司债券（以下简称"可转债"）转股及公司股 份变动的情况公告如下： 一、可转债发行上市概况 （一）可转债发行上市基本情况 经中国证券监督管理委员会"证监许可[2020]1830 号"文同意注册的批复，公 司于 2020 年 9 月 1 日向不特定对象发行了 600 万张可转换公司债券，每张面值 100 元，发行总额 6.00 亿元。 经深交所同意，公司 6.00 亿元可转换公司债券将于 2020 年 9 月 23 日起在 深交所挂牌交易，债券简称"万孚转债"，债券代码"123064"。 （二）可转债转股价格调整情况 根据《深圳证券交易所创业板股票上市规则》等规定和《广州万孚生物技术 股份有限公司向不特定对象发行可转换公司债券募集说明书》 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Guangzhou Wanfang Biological Technology Co., Ltd, particularly in the medical device industry [1][2] - As of June 24, the company's stock price closed at 21.06 yuan, with a rolling PE ratio of 19.04 times and a total market capitalization of 10.139 billion yuan [1] - The average PE ratio for the medical device industry is 49.12 times, with a median of 36.07 times, placing Wanfang Biological at the 45th position in the industry ranking [1] - The company reported a revenue of 800 million yuan for Q1 2025, reflecting a year-on-year decrease of 7.06%, and a net profit of 189 million yuan, down 13.37% year-on-year, with a gross profit margin of 66.67% [2] Group 2 - As of March 31, 2025, the number of shareholders for Wanfang Biological increased to 42,296, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company's main business includes the research, production, and marketing of rapid diagnostic reagents and related instruments, focusing on infectious disease testing, chronic disease testing, pregnancy and reproductive health testing, and drug abuse testing [1] - Wanfang Biological has received numerous accolades, including being recognized as a key high-tech enterprise under the National Torch Program and a national-level "green factory" in January 2025 [1]

Core Viewpoint - The credit rating agency has assigned a stable outlook to Guangzhou Wanfeng Biotechnology Co., Ltd. (Wanfeng Bio), reflecting its strong product line, significant R&D investment, and robust financial health despite facing industry challenges such as price pressures and increased competition [4][6][7]. Company Overview - Wanfeng Bio operates in the field of rapid diagnostic reagents and related instruments, with a diverse product line covering cardiovascular diseases, inflammation, tumors, infectious diseases, and drug abuse testing [4][16]. - The company has a global market presence, covering over 150 countries and regions, which helps mitigate operational risks [4][16]. Financial Performance - For the first quarter of 2025, Wanfeng Bio reported revenue of 800 million yuan, a year-on-year decrease of 7.06% [6]. - The company's total assets as of March 2025 were 7.183 billion yuan, with total liabilities of 596 million yuan, indicating a low debt level [5]. - The net profit for the same period was 190 million yuan, down from 565 million yuan in the previous year [5]. R&D and Product Development - Wanfeng Bio has increased its R&D investment, with 438.38 million yuan allocated in 2024, representing 14.30% of its revenue [16]. - The company launched 82 new products in 2024, including 75 reagent projects and 7 instruments, enhancing its product matrix [16]. Market Challenges - The industry is experiencing price pressures due to the normalization of centralized procurement and increased competition, particularly in the domestic market [6][12]. - The company faces uncertainties regarding the impact of tax changes on its reagent products, which shifted from simplified taxation to a general tax rate of 13% at the beginning of 2025 [6][12]. Future Outlook - Wanfeng Bio's credit rating outlook remains stable, supported by its diverse technology platforms and product lines, although it must navigate ongoing pricing pressures and competitive dynamics in the market [7][12]. - The company is expected to continue expanding its R&D efforts and product offerings to maintain its market position and drive future growth [4][16].

Group 1 - The core index, the China Securities Social Development Security Industry Theme Index, rose by 1.21% to 1596.77 points, with a trading volume of 34.7 billion yuan [1] - Over the past month, the index has decreased by 1.85%, down 11.26% over the last three months, and down 3.54% year-to-date [1] - The index includes no more than 100 securities from companies benefiting from social development security, covering sectors such as information security, environmental security, security equipment, and safety testing [1] Group 2 - The top ten holdings of the index are: Huace Testing (9.48%), Hikvision (8.05%), Zhongke Shuguang (3.6%), Wanfu Biology (2.93%), Meiya Optoelectronics (2.91%), Greeenmei (2.87%), Nanwang Technology (2.6%), Dahua Technology (2.43%), Aerospace Zhizhuang (2.35%), and Siwei Liekong (2.34%) [1] - The market share of the index's holdings is 67.16% from the Shenzhen Stock Exchange and 32.84% from the Shanghai Stock Exchange [1] Group 3 - The industry composition of the index's sample includes: 42.47% in industrials, 41.80% in information technology, 5.47% in utilities, 4.93% in communication services, 4.89% in healthcare, and 0.45% in finance [2] - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December [2] Group 4 - Public funds tracking the index include Donghai China Securities Social Development Security [3]

本评级机构依据内部信用评级标准和工作程序对评级结果作出独立判断，不受任何组织或个人的影响。 本评级报告观点仅为本评级机构对评级对象信用状况的个体意见，不作为购买、出售、持有任何证券的 建议。本评级机构不对任何机构或个人因使用本评级报告及评级结果而导致的任何损失负责。 广州万孚生物技术股份有限公司 相关债券 2025 年跟踪评级报告 中鹏信评【2025】跟踪第【256】号 02 信用评级报告声明 除因本次评级事项本评级机构与评级对象构成委托关系外，本评级机构及评级从业人员与评级对象不存 在任何足以影响评级行为独立、客观、公正的关联关系。 本评级机构与评级从业人员已履行尽职调查义务，有充分理由保证所出具的评级报告遵循了真实、客观、 公正原则，但不对评级对象及其相关方提供或已正式对外公布信息的合法性、真实性、准确性和完整性 作任何保证。 本次评级结果自本评级报告所注明日期起生效，有效期为被评证券的存续期。同时，本评级机构已对受 评对象的跟踪评级事项做出了明确安排，并有权在被评证券存续期间变更信用评级。本评级机构提醒报 告使用者应及时登陆本公司网站关注被评证券信用评级的变化情况。 本评级报告版权归本评级机构所有，未经 ...

Core Viewpoint - The company Wanfu Biological has reported a decline in revenue and net profit for Q1 2025, while its PE ratio remains significantly lower than the industry average, indicating potential undervaluation in the context of the medical device sector [1][2]. Company Summary - Wanfu Biological's closing stock price is 21.01 yuan, down 1.22%, with a rolling PE ratio of 19.00 times and a total market capitalization of 10.115 billion yuan [1]. - The company specializes in the research, production, and marketing of rapid diagnostic reagents and related instruments, focusing on infectious disease testing, chronic disease testing, pregnancy and reproductive health testing, and drug abuse testing [1]. - As of Q1 2025, nine institutions hold shares in Wanfu Biological, with a total of 81.10 million shares valued at 1.873 billion yuan [1]. Industry Summary - The average PE ratio for the medical device industry is 49.10 times, with a median of 36.43 times, positioning Wanfu Biological at the 46th rank within the industry [1][2]. - The company's Q1 2025 performance shows a revenue of 800 million yuan, a year-on-year decrease of 7.06%, and a net profit of 189 million yuan, down 13.37% year-on-year, with a gross margin of 66.67% [2]. - The company has received multiple accolades, including being recognized as a national high-tech enterprise and a national-level "green factory" [1].

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-031 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于终止实施 2024 年限制性股票激励计划暨回购注销 限制性股票的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误 导性陈述或者重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"或"万孚生物"） 于 2025 年 6 月 18 日召开第五届董事会第十二次会议、第五届监事会第九次会议，审议 通过了《关于终止实施 2024 年限制性股票激励计划暨回购注销限制性股票的议 案》。根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）《2024 年限 制性股票激励计划（草案）》（以下简称"《激励计划》"或"本次激励计划"）的 规定，公司结合实际情况，决定终止实施 2024 年限制性股票激励计划。因公司 拟终止实施 2024 年限制性股票激励计划，激励对象已获授但尚未解除限售的限 制性股票将由公司回购注销。本议案尚需提交股东大会审议。现将具体事项公告 如下: 一、本 ...

北京市君合（广州）律师事务所 关于 二〇二五年六月 广州万孚生物技术股份有限公司 终止实施 2024 年限制性股票激励计划暨 回购注销限制性股票 的 法律意见书 释 义 在本法律意见书中，除非文义另有所指，下列词语、简称或专业术语具有如下含义： | 简称 | 指 | 全称或含义 | | --- | --- | --- | | 本次激励计划、《激励 | 指 | 《广州万孚生物技术股份有限公司 2024 年限制性股 | | 计划》 | | 票激励计划》 | | 公司/上市公司/万孚 | 指 | 广州万孚生物技术股份有限公司 | | 生物 | | | | 本法律意见书 | 指 | 《北京市君合（广州）律师事务所关于广州万孚生物 技术股份有限公司终止实施 2024 年限制性股票激励 | | | | 计划暨回购注销限制性股票的法律意见书》 | | 深交所 | 指 | 深圳证券交易所 | | 《公司章程》 | 指 | 《广州万孚生物技术股份有限公司章程》 | | 《公司法》 | 指 | 《中华人民共和国公司法》 | | 《证券法》 | 指 | 《中华人民共和国证券法》 | | 《管理办法》 | 指 | 《上市公司股权激励 ...